Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blink is a brand of over-the-counter lubricant eye drops (artificial tears) primarily used to provide temporary relief from ocular dryness, burning, and irritation. The formulation typically utilizes polyethylene glycol 400 (PEG 400) as a demulcent, which functions by stabilizing the tear film and increasing moisture retention on the ocular surface. In the context of clinical research sponsored by Bp Consulting, Inc., Blink was evaluated in a Phase 4 trial (NCT00703300) as an adjunct or control intervention for patients with diabetic macular edema (DME) undergoing argon laser therapy. In this capacity, it serves as a moisturizing agent to maintain ocular surface integrity and comfort during the treatment of retinal vascular disorders, often serving as a comparator to active pharmaceutical interventions like bromfenac.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Blink.